Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Tentang
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Show more...
CEO
Dr. Jan Skvarka
Karyawan
33
Negara
CA
Pencatatan
0 Comments
Bagikan pendapatmu
FAQ
Berapa harga saham Trillium Therapeutics hari ini?▼
Harga saat ini dari TRIL.TO adalah C$23.33 CAD — naik sebesar +0.47% dalam 24 jam terakhir. Pantau kinerja harga saham Trillium Therapeutics lebih dekat di grafik.
Apa simbol saham Trillium Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Trillium Therapeutics diperdagangkan dengan simbol TRIL.TO.
Berapa jumlah karyawan Trillium Therapeutics?▼
Per April 01, 2026, perusahaan memiliki 33 karyawan.
Trillium Therapeutics berada di sektor apa?▼
Trillium Therapeutics beroperasi di sektor Healthcare.